Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Antengene Corporation Limited
  6. News
  7. Summary
    6996   KYG039571008

ANTENGENE CORPORATION LIMITED

(6996)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Antengene : Founder And CEO Of Antengene, Dr. Jay Mei, Talks Innovation In Biotech, Passion And Learning From Our Mistakes (Podcast)

06/11/2021 | 06:10am EDT

In this episode

Aasmah talks to Dr Jay Mei about how science is changing the world, why he is passionate about pharmaceuticals and what he has learnt from his experiences.

Podcast host: Aasmah Mir

Aasmah Mir is an award winning broadcaster and journalist. She currently co-hosts the Breakfast Show on Times Radio and writes a regular column for The Times.

Guest: Dr Jay Mei

Dr. Mei has nearly 30 years of experience in clinical research and development of oncology therapeutics globally. He has published over 70 publications and is the co-inventor of multiple patents.

In the 1990s, Dr. Mei dedicated himself to extensive cancer research at the National Cancer Institute in the United States. In 2001, Dr. Mei joined as a Principal Scientist in the oncology team in the drug discovery division and Associate Director at Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. From 2006, Dr. Mei worked as a Senior Director at Novartis Oncology, part of the Innovative Medicines division of Novartis AG. From 2008 to 2017, he served as an Executive Director of the clinical development department at Celgene (now part of Bristol-Myers Squibb). At Celgene, Dr. Mei was one of the leading members in the clinical development of multiple blockbuster drugs that represent the most significant part of Celgene's portfolio today, including REVLIMID®, which is among the best-selling oncology therapies worldwide, and was also involved in the clinical development of POMALYST®, also one of the best-selling oncology drugs worldwide, and IDHIFA®, a first-in-class drug for the treatment of acute myeloid leukemia.

Dr. Mei has been a member of the American Society of Hematology since 2006 and was involved in the management of Antengene since April 2017. Dr. Mei also currently holds adjunct professorship at the Baruch S. Blumberg Institute.

Dr. Mei received his Doctor of Medicine (M.D.) degree from Hunan Medical University (now Xiangya School of Medicine of Central South University) in China and obtained his Doctor of Philosophy (Ph.D.) degree in pharmacology and toxicology from the University of Maryland in U.S.A.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Withers LLP
Withers LLP
16 Old Bailey
London
EC4M 7EG
UK
Tel: 2075976000
Fax: 2075976543
E-mail: digital@withers.net
URL: www.withersworldwide.com

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about ANTENGENE CORPORATION LIMITED
09/15Antengene Selected as a Constituent of the FTSE Global Equity Index Series
DJ
09/03ANTENGENE : Cancer Treatment Gets Approval for Phase 1 Clinical Trial in Australia; Shares..
MT
08/23ANTENGENE : Gets Chinese Regulator Nod for Phase 2 Trial of Potential Myelofibrosis Treatm..
MT
08/23ANTENGENE : Announces Approval of the Phase II Study of Selinexor for the Treatment of Mye..
PR
08/23Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for..
CI
08/23Antengene Narrows H1 Loss on Lower Research and Development Costs
MT
08/20Antengene Corporation Limited Announces Unaudited Consolidated Earnings Results for the..
CI
08/08Antengene Corporation Limited and MindRank AI Enter into Collaboration to Advance the D..
CI
08/02KARYOPHARM THERAPEUTICS : Partner Antengene Says Cancer Drug Xpovio Gets Approval in South..
MT
07/30ANTENGENE : Voluntary announcement approval of nda by the mfds for atg-010 (selinexor) for..
PU
More news
Financials
Sales 2021 2,00 M 0,31 M 0,31 M
Net income 2021 -752 M -116 M -116 M
Net cash 2021 3 307 M 512 M 512 M
P/E ratio 2021 -8,46x
Yield 2021 -
Capitalization 6 621 M 1 024 M 1 024 M
EV / Sales 2021 1 657x
EV / Sales 2022 23,2x
Nbr of Employees 219
Free-Float 56,2%
Chart ANTENGENE CORPORATION LIMITED
Duration : Period :
Antengene Corporation Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTENGENE CORPORATION LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 9,86 CNY
Average target price 22,02 CNY
Spread / Average Target 123%
EPS Revisions
Managers and Directors
Jian Ming Mei Chairman & Chief Executive Officer
Donald Andrew Lung Chief Financial Officer & Executive Director
Bo Shan Chief Scientific Officer
Kevin Lynch Executive Director & Chief Medical Officer
Yiteng Liu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ANTENGENE CORPORATION LIMITED-30.69%1 024
GILEAD SCIENCES, INC.22.52%89 936
BIONTECH SE316.17%82 443
WUXI APPTEC CO., LTD.36.63%69 407
REGENERON PHARMACEUTICALS33.94%67 262
VERTEX PHARMACEUTICALS-22.03%48 202